Abstract
This study is a meta-analysis comparing the efficacy, predictability, and safety of correcting myopia via implantation of two types of phakic intraocular lens (PIOLs): the implantable collamer lens (ICL) and iris-fixed PIOL. The Cochrane library, Pubmed, and EMBASE were searched. Study selection, data exclusion, and quality assessment were performed by two independent observers. The pooled relative risk (RR), pooled standardized mean difference (SMD), and their 95% confidence intervals (CIs) were used to compare lenses. Seven studies, involving 511 eyes, were included. The pooled SMD in postoperative uncorrected distance visual acuity (UDVA) comparing ICLs to iris-fixed PIOLs was −0.22 (95% CI, −0.58 to 0.13; P = .22). The pooled RR values of UDVA of 20/20 or better and of 20/40 or better comparing ICLs to iris-fixed PIOLs were 1.15 (95% CI, 0.89 to 1.47; P = .29) and 1.01 (95% CI, 0.95 to 1.08; P = .75), respectively. The pooled RR of loss of best spectacle-corrected visual acuity (BSCVA) and gain in BSCVA comparing ICLs to iris-fixed PIOLs were 1.20 (95% CI, 0.24 to 6.00; P = .82) and 1.14 (95% CI, 0.89 to 1.48; P = .31), respectively. The pooled RR comparing ICLs to iris-fixed PIOLs was 0.78 (95% CI, 0.29 to 2.12; P = .63) for all reported complications and 2.80 (95% CI, 1.04 to 7.52; P = .04) for severe complications. The pooled RR of achieving a result within ±0.5 D (diopter) of the intended target comparing ICLs to iris-fixed PIOLs was 1.35 (95% CI, 1.04 to 1.77; P = .03). Overall, there is no significant difference in efficacy between the two types of PIOLs or in safety, except that the ICL is associated with a greater incidence of severe complications, especially anterior subcapsular cataract, primarily in the Version 2 and Version 3 groups. However, ICL has better predictability.
Highlights
Refractive surgeries, including laser corneal refractive surgery, phakic intraocular lens (PIOL) implantation, and clear lens extraction (CLE) are among the approaches which have been developed to treat myopia and high myopia
V3 implantable collamer lens (ICL) were associated with a 9.2% incidence of cataract versus 0.8% for V4 ICLs (P,.001), according to the Food and Drug Administration (FDA) clinical trial [39], we found no significant difference in severe complications between the groups (RR = 2.06; 95% confidence intervals (CIs), 0.65 to 6.52; P = .22; I2 = 0.0%)
Some studies compared refractive outcomes between these PIOLs, the conclusions differed, and no review has performed a systematic comparison of ICL and iris-fixed PIOL implantation for myopia
Summary
Refractive surgeries, including laser corneal refractive surgery, phakic intraocular lens (PIOL) implantation, and clear lens extraction (CLE) are among the approaches which have been developed to treat myopia and high myopia. Barsam et al [8] reported that PIOL implantation is a safer method of correcting myopia in the range of 26.00 D to 220.00 D, effecting significantly less loss of best spectaclecorrected visual acuity (BSCVA) and better contrast sensitivity than corneal refractive surgery. With its reversibility, correction of a broader range of ametropia, preserved accommodation, faster visual recovery, more stable refraction, and better visual quality [9,10,11], PIOL implantation is gaining traction with more patients and refractive surgeons
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have